Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000^® Index and the broad-market Russell 3000^® Index, effective today.

“MindMed’s inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism spectrum disorder,” said Rob Barrow, Chief Executive Officer of MindMed. “We are pleased to join the Russell Indexes and look forward to continuing to share our story with a broader audience of investors.”

Membership in the Russell 3000^® Index means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index as well as in the appropriate growth and value style indexes. The Russell 3000^® Index encompasses the 3,000 largest U.S.-traded stocks by objective, market-capitalization rankings, and style attributes. Membership in these indexes is updated annually and remains in place for one year.

The Russell Indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9.1 trillion in assets are benchmarked against Russell's U.S. Indexes. Russell Indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell Indexes and the Russell U.S. Indexes Reconstitution, visit the "Russell Reconstitution" section on the FTSE Russell website.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine, and acetylcholine systems.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240628586419/en/